The relationship between exposure to hepatitis B virus and increased atherosclerosis-associated morbidity — a meta-analysis

Chen-guang Li¹,*; Song-jie Liao¹*; Jia-li Que²; Ke-jia Liu¹; Hao-yue Wang¹; Jian Yu¹

¹Department of Neurology, Guangdong Key Laboratory for Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department, National Key Discipline, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
²Department of Neurology, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, China
*Chen-guang Li and Song-jie Liao contributed equally to this study.

Abstract

Background and aim: The relationship between exposure to hepatitis B virus (HBV) and atherosclerosis-associated disease morbidity has not been clearly elucidated. We performed a meta-analysis to explore whether exposure to HBV is a risk factor for atherosclerosis-associated diseases.

Methods: We searched the PubMed, Web of Science, Cochrane Library, Embase, and Scopus databases for related studies. We then chose the eligible studies for meta-analysis and assessed quality assessment and risk of bias.

Results: The meta-analysis of the included studies showed that exposure to HBV tends to increase atherosclerosis-associated disease morbidity, but this increase was not statistically significant.

Conclusions: Hepatitis B virus may not be a risk factor for atherosclerosis-associated diseases, but further studies that employ more sensitive clinical parameters are needed to verify this result.

Key words: hepatitis B virus, atherosclerosis, meta-analysis

INTRODUCTION

Atherosclerosis is a common disease with increasing morbidity, which is associated with many cardiovascular and cerebrovascular diseases, including coronary heart disease (CHD) and stroke. The traditional risk factors for atherosclerosis, such as arterial hypertension, diabetes mellitus, and hyperlipidaemia, are well known. However, in clinical practice, certain patients with atherosclerosis do not have the risk factors mentioned above, and this observation highlights the importance of identifying novel risk factors that might contribute to atherosclerosis.

Previous studies have demonstrated that inflammation caused by infection, especially chronic infection, is one of the risk factors for atherosclerosis-associated diseases [1]. A meta-analysis showed that chronic hepatitis C virus (HCV) infection increases atherosclerosis-associated disease mortality [2]. However, in China, in particular South China, the morbidity of hepatitis B virus (HBV) is far higher than that of HCV [3]. Thus, determination of the relationship of exposure to HBV with atherosclerosis-associated diseases merits more attention. Moreover, studies have shown that exposure to HBV could promote oxidative stress [4], increase mean platelet volume (MPV) [5], and affect blood lipid levels [6], all of which can increase atherosclerosis risk.

However, whether exposure to HBV can increase the morbidity of atherosclerosis-associated diseases is controversial [7–13]. In this study, we reviewed relevant studies and performed a meta-analysis to explore whether exposure to HBV is a risk factor for atherosclerosis.
**METHODS**

**Search strategies**

We searched for keywords “atherosclerosis or atherosclerotic or arteriosclerosis” and “hepatitis B or hepatitis B virus or HBV” in the “all fields” function of PubMed, Web of Science, Cochrane Library, Embase, and Scopus databases from 1986 to February 13, 2016. No language restrictions were applied to the search strategy. The results were sent to reference management software and duplicates were deleted. Two reviewers (C. L. and S. L.) independently screened the title and abstract of each article and then decided whether the article met the inclusion criteria. In the event of differences in opinion, the two reviewers discussed their opinions and decided whether to include the article in the final analysis.

**Inclusion and exclusion criteria**

The inclusion criteria were: (1) exposure to HBV; (2) outcome of atherosclerosis-associated disease, such as CHD, carotid atherosclerosis, and stroke (diagnosed based on standard criteria); and (3) observational study (including cross-sectional study, case-control study, and cohort study). For example, a case-control study was included if it compared the exposure to HBV between individuals with and without CHD.

The exclusion criteria were: (1) concurrent infection with other pathogens; (2) if the relationship between exposure to HBV and atherosclerosis-associated diseases were not studied; and (3) review, workshop summary, animal experiment, and other no observational study.

**Quality assessment**

Two reviewers (C. L. and S. L.) independently assessed the quality of the studies, according to the Newcastle-Ottawa Scale [14]. The Newcastle-Ottawa Scale assesses the quality of a study based on three aspects: selection, comparability, and exposure. Selection includes four sub-items: adequate case definition, representativeness of the cases, selection of controls, and definition of controls. Comparability pertains to the comparability of case and control when it comes to design and statistical analysis, which includes the important factors and the additional factors. Exposure includes three sub-items: ascertainment of exposure, same method of ascertainment for cases and controls, and non-response rate. If the study fits one sub-item, it is awarded one star; thus, more stars represent higher quality.

**Data abstraction**

Two reviewers (C. L. and S. L.) decided the item, format, and unit of the data of each eligible study, after discussion. They independently abstracted the necessary data. Finally, the reviewers checked the data and counterchecked the article in case of differences.

**Analysis**

We performed a meta-analysis of eligible studies using the software Review Manager 5.3, and presented results as odds ratio (OR), 95% confidence interval (95% CI), and p value. The forest plot was drawn by Review Manager 5.3. The risk of publication bias assessment was analysed by funnel plot and Egger test. The funnel plot was drawn by Review Manager 5.3, and the Egger test was performed by Stata 12.0. A p value < 0.05 was considered statistically significant.

**RESULTS**

**Study identification and selection**

After searching the PubMed, Web of Science, Cochrane Library, Embase, and Scopus databases, 1071 relevant articles were identified, of which 320 were duplicates and were deleted. The two reviewers screened the titles and abstracts of 751 articles and identified 29 articles that met the inclusion criteria. In the event of differences in opinion, the two reviewers discussed their opinions before deciding whether to include the article in the final analysis. The authors then read the full text of all 29 articles, and excluded studies that were not suitable for this meta-analysis. Eleven articles were excluded because they were the incorrect type of articles, such as reviews and workshop summaries; five articles had the wrong methodology (three included patients who had concurrent infection with other pathogens); one article was a cross-sectional study and did not study the relationship between exposure to HBV and atherosclerosis [15]; one article that considered cerebrovascular disease as an outcome included both ischaemic and haemorrhagic cerebrovascular disease [7]; seven articles had the wrong outcomes (they studied the parameters related to atherosclerosis but did not set a threshold to define atherosclerosis) [4–6, 16–19]; and one article was a cohort study, but there was no other cohort study to perform the meta-analysis [11]. Finally, we included five eligible studies for the meta-analysis [8–10, 12, 13]. This process is shown in Figure 1.

**Characteristics of the studies**

We collected the year, country, and other characteristics of the five studies (Table 1). The atherosclerosis-associated diseases in these studies included only two types: CHD and carotid atherosclerosis. The diagnosis of atherosclerosis-associated diseases in these five studies fitted the standard diagnostic criteria. The number of patients ranged from 434 to 5044. All studies included both men and women. Only the studies by Amirzadegan et al. [12] and Tong et al. [9] mentioned the storage temperature of serum samples (Table 1).

**Risk of bias assessment**

The risk of bias assessment is shown in Table 2. The selections of all studies were appropriate. Among four studies that used CHD as their outcome, patients’ diagnoses were confirmed by coronary angiography, which documented stenosis > 50% [8, 9, 12, 13]. In one study that used carotid atherosclerosis...
as the outcome, the diagnoses were confirmed by B-mode ultrasonography, which demonstrated focal thickening of the intima-media layer ≥ 1.3 mm [10]. With the exception of the study by Ishizaka et al. [10], the other four studies all included hospitalised patients as controls. All the five studies considered sex, age, and other confounding factors. With the exception of the study by Amirzadegan et al. [12], which diagnosed HBV exposure by detecting the presence of anti-HBV in patients who had never had HBV infection or received the HBV vaccine, and the study by Tong et al. [9], which diagnosed HBV exposure by detecting the presence of one of the two antigens and three antibodies, all other studies diagnosed HBV infection by the presence of hepatitis B surface antigen (HbsAg) (Table 2).

**Risk of publication bias assessment**
We have drawn the funnel plot and performed the Egger test for the five included studies. The funnel plot shows that the distribution of the eligible studies is similar to a funnel (Fig. 3), and the Egger test shows a p value of 0.915. Thus, there is no publication bias in these five studies.

**DISCUSSION**
Meta-analysis of five eligible studies showed that exposure to HBV tends to increase the risk of atherosclerosis-associated diseases, but this increase is not statistically significant. Recently, a similar study reported that HBV infection did not increase the risk of coronary artery diseases [20]. It does not seem that exposure to HBV would increase cardiovascular event morbidity. Nevertheless, exposure to HBV can affect not only the coronary artery, but also cerebrovascular, carotid artery, and other blood vessels. Thus, we chose “atherosclerosis or atherosclerotic or arteriosclerosis” as the key words of our search, and included the studies with the outcomes of CHD, carotid atherosclerosis, and stroke. In our study, the outcome of four studies is CHD, and the outcome of one study is carotid atherosclerosis. However, there is no study report regarding the relationship between exposure to HBV and stroke.
### Table 1. Study characteristics

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Study design</th>
<th>Country</th>
<th>Study outcomes</th>
<th>Storage of serum samples</th>
<th>No. of subjects</th>
<th>Mean age [years]</th>
<th>Male [%]</th>
<th>Hypertension [%]</th>
<th>Diabetes [%]</th>
<th>Mean cholesterol [mmol/L]</th>
<th>Mean triglyceride [mmol/L]</th>
<th>BMI [kg/m²]</th>
<th>Smokers [%]</th>
</tr>
</thead>
</table>
| Ghotaslou et al., 2008 [11] | Case-control | Iran | CAD | HBsAg | NR | HBV+ 159 | NR | NR | NR | NR | NR | NR | NR 
| Amirzadegan et al., 2007 [15] | Case-control | Iran | CAD | Anti-HBS | −80°C | HBV+ 239 | 57.18 | 71.1 | 35.6 | 18.8 | 5.3 | 2.1 | 27.61 | 29.7 |
| Tong et al., 2005 [12] | Case-control | China | CAD | HBsAg, HBeAg, anti-HBs, anti-HBc | −70°C | HBV+ 329 | 62.12 | 70.2 | 62.3 | 14.6 | NR | NR | 32.8 |
| Momiyama et al., 2005 [16] | Case-control | Japan | CAD | HBsAg | NR | HBV+ 6 | NR | NR | NR | NR | NR | NR | NR |
| Ishizaka et al., 2002 [13] | Case-control | Japan | CA | HBsAg | NR | HBV+ 40 | 58 | 65 | NR | NR | 5.1 | 1.1 | 23.1 | 18 |
| Ishizaka et al., 2002 [13] | Case-control | Japan | CA | HBsAg | NR | HBV+ 4646 | 57 | 67 | NR | NR | 5.4 | 1.5 | 23.2 | 27 |

BMI — body mass index; CA — carotid atherosclerosis; CAD — coronary artery disease; HBV — hepatitis C virus; NR — not reported

### Table 2. Newcastle-Ottawa Scale

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>Selection</th>
<th>Comparability</th>
<th>Exposure</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ghotaslou et al., 2008 [11]</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>1,2,3,4,5,6</td>
</tr>
<tr>
<td>Amirzadegan et al., 2007 [15]</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>1,2,3,4,5,6,7</td>
</tr>
<tr>
<td>Tong et al., 2005 [12]</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>1,2,3,4,5,6</td>
</tr>
<tr>
<td>Momiyama et al., 2005 [16]</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>1,2,3,4,5,6</td>
</tr>
<tr>
<td>Ishizaka et al., 2002 [13]</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>1,2,3,4,6</td>
</tr>
</tbody>
</table>

Important factors: 1 — age; 2 — sex; 3 — hyperglycaemia; 4 — hypertension; 5 — diabetes; 6 — smoking; 7 — body mass index. Five items or more get one star.

Additional factors: 8 — C-reactive protein; 9 — alanine transaminase; 10 — history of cardio-cerebrovascular diseases; 11 — family history; 12 — other infectious diseases; 13 — others.

Two items or more get one star.
This finding is similar to that obtained by Sung et al. [11] in a cohort study that was excluded in this analysis. Among four studies that used CHD as the main outcome, and which confirmed patients’ diagnosis by coronary angiogram showing stenosis > 50%, there was no statistically significant effect of HBV on atherosclerosis risk. Thus, we consider that diagnosing CHD using a coronary angiogram may be more accurate, but less sensitive in diagnosing atherosclerosis compared with carotid atherosclerosis. So, in our opinion there might be some pathologic changes when exposing to HBV, although exposure to HBV does not increase cardiovascular event morbidity. Furthermore, a study found that exposure to HBV increases the intima-media thickness [19]. Increased oxidative stress [4] and MPV [5] caused by exposure to HBV mainly affect the early pathological changes seen in atherosclerosis. Meanwhile, studies that showed a positive relationship between HCV infection and increased atherosclerosis-associated disease morbidity mainly used carotid atherosclerosis as the outcome of interest [21]. Thus, it is necessary to explore the relationship between exposure to HBV and atherosclerosis-associated diseases using a more sensitive parameter.

Furthermore, another study considered that exposure to HBV can decrease the risk of atherosclerosis, which was related to hepatic dysfunction caused by exposure to HBV, and the authors confirmed this hypothesis in a subgroup analysis [11]. This finding may be attributed to the pivotal role of the liver in coagulation factor synthesis and lipid metabolism. In addition, the secondary hypersplenism caused by liver cirrhosis can lead to thrombocytopenia. All the factors mentioned above can play important roles in atherosclerosis.

**Limitations of the study**

Our study has some limitations. First, the number of included articles was small, which may be attributed to the lack of studies on the relationship between exposure to HBV and atherosclerosis and the possibility that studies with negative findings were scarce. Second, the included studies were mainly from Asian countries, which may be attributed to the high HBV morbidity in Asian countries compared with other countries. However, given that differences in race exist in the reaction of vascular endothelial cells to infection [22], further research is warranted to investigate the relevance of race in HBV-related atherosclerosis risk.

**CONCLUSIONS**

Thus, we think that the influence of exposure to HBV to atherosclerosis depends on the function of the liver. When the function of the liver is normal, exposure to HBV can increase the risk of atherosclerosis, especially during the early stage of pathological atherosclerotic lesions. Conversely, when exposure to HBV leads to hepatic dysfunction, it can decrease the risk of atherosclerosis. However, this hypothesis requires further investigation in order to be confirmed or refuted.

**Funding:** This work was supported by the project of the National Natural Science Foundation of China (No. 81371276) and the National Science Foundation of Guangdong Province, China (No. 2014A030313065) to J.Y. It was also supported by the Medical Scientific Research Foundation of Guangdong Province, China (No. A2015480) to S.L.

**Conflict of interest:** none declared
References


